Combining immunotherapy and AlphaFold to improve outcomes in oral squamous cell carcinoma (OSCC) treatment | Synapse
March 3, 2026Open Access
Combining immunotherapy and AlphaFold to improve outcomes in oral squamous cell carcinoma (OSCC) treatment
Key Points
Improved outcomes in oral squamous cell carcinoma highlight a potential enhancement from combining immunotherapy and AlphaFold.
Key evidence includes specific tumor antigens identified through AlphaFold, which may heighten immunotherapy efficacy.
Analysis leverages artificial intelligence to improve the specificity of treatment approaches for oral squamous cell carcinoma.
This combination may enable more effective targeting of therapies, addressing unmet needs in cancer treatment.
Abstract
• Alphafold and immunotherapy in oral oncology • Enhancing the effects of immunotherapy through AI • Identification of specific tumor antigens via AlphaFold